Intangible assets consist of licenses of intellectual property acquired by the Group through various agreements with third parties and are recorded at the value of the consideration transferred. Information regarding the cost and accumulated amortization of intangible assets is as follows:


Cost			Licenses $



Balance as of January 1, 2022			990
Additions			25
Impairment			(163)
Deconsolidation of subsidiary			(21)
Balance as of December 31, 2022			831
Additions			200
Impairment			(105)
Deconsolidation of subsidiaries			(19)
Balance as of December 31, 2023			906


Accumulated amortization			Licenses $



Balance as of January 1, 2022			(3)
Amortization			(1)
Deconsolidation of subsidiary			4
Balance as of December 31, 2022			—
Amortization			—
Deconsolidation of subsidiary			—
Balance as of December 31, 2023			—


Intangible assets, net			Licenses $


Balance as of December 31, 2022			831
Balance as of December 31, 2023			906

Substantially all the intangible asset licenses represent in-process-research-and-development assets since they are still being developed and not ready for their intended use. As such, these assets are not amortized but tested for impairment annually.

During the year ended December 31, 2023, the Group wrote off two of its research intangible assets for which research was ceased in the amount of $105.

During the year ended December 31, 2023, Vedanta , Inc. was deconsolidated and as such, $19 net in intangible assets were derecognized.

During the year ended December 31,2022, the Group wrote off one of its research intangible assets for which research was ceased in the amount of $163.

During the year ended December 31, 2022, Sonde Health, Inc. was deconsolidated and as such, $18 net intangible assets were derecognized.

The Group tested all intangible assets for impairment as of the balance sheet date and concluded that none of such assets were impaired.